About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Obesity and Pediatric Multiple Sclerosis | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGNCT04593082

Obesity and Pediatric Multiple Sclerosis

Obesity is one possible contributor to severity of multiple sclerosis and progression of the disease. We already know that obesity is a risk determinant for acquiring MS, yet the impact of obesity on ...

Lead sponsor: University of Virginia•2 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

J Nicholas Brenton, MD

CONTACT

434-982-3936 jnb8h@virginia.edu

Margaret Keller

CONTACT

434-297-4102 mfk8e@hscmail.mcc.virginia.edu

Sponsors

Lead Sponsor

University of Virginia

Collaborators

Children's Hospital of Philadelphia

Age

10 - 20 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Ability to provide informed consent (or assent for minors)
•Relapsing-remitting MS diagnosis per 2017 McDonald criteria
•Ages ≥ 10 years to ≤ 20 years
•Diagnosis of MS or first clinical symptom of MS (whichever comes first) within ≤ 36 months from the time of enrollment.
•Ability to provide informed consent (or assent for minors)
•Age-, sex-, \& BMI-matched to pediatric MS subjects (1:1 allocation)
•Healthy children and young adults from the local communities

Exclusion Criteria

•Progressive form of MS
•Patients with an active, chronic disease of the immune system other than MS
•Conditions affecting the central nervous system (CNS) white matter (e.g. leukodystrophy) or for whom another condition may better explain imaging abnormalities (e.g. lupus)
•Myelin oligodendrocyte glycoprotein (MOG) antibodies on serologic testing
•Corticosteroid exposure within 30 days of study enrollment
•History of past imaging or neurologic event raising concern for any inflammatory CNS process
•Medical history or previous/current diagnosis consistent with an autoimmune disorder pertaining to any system of the body (e.g. diabetes mellitus type 1, Crohn's disease, lupus)

Related studies

Development of Pain Management JITAI Content in Multiple Sclerosis and Spinal Cord Injury

NCT07663266 · Multiple Sclerosis, Spinal Cord Injury

RECRUITINGPhase 3

A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

NCT07189325 · Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy

RECRUITINGPhase 2

Solriamfetol for the Treatment of Multiple Sclerosis Fatigue

NCT06170970 · Multiple Sclerosis, Multiple Sclerosis Fatigue

RECRUITINGPhase 2

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

NCT06782490 · Multiple Sclerosis Spasticity

RECRUITINGPhase 3

A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

NCT07299019 · Secondary Progressive Multiple Sclerosis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 9, 2024Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment116

Start dateJun 2021

Last updatedDec 9, 2024

Condition

Multiple Sclerosis

Locations shown

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania

University of Virginia

Charlottesville, Virginia

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 9, 2024Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions